PRESCRIPTION DRUG MONITORING PROGRAM TRAINING AND TECHNICAL ASSISTANCE CENTER
The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) at the Institute for Intergovernmental Research (IIR) provides a comprehensive array of services, support, resources, & strategies to PDMPs, federal partners and other stakeholders to further the efforts and effectiveness of PDMPs in combating the misuse and diversion of prescription drugs.
News & Events
-
Aggregate Production Quota (APQ) Adjustments
Read More November 10, 2026November 10, 2026 Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) (opens in a new tab) in accordance with 21 U.S.C. 826(a) (opens in a new tab) and is expediting publication of this determination to comply with the timeframes specified in 21 U.S.C. 826(h)(1) (opens in a new tab). This final order is effective November 10, 2026.
November 10, 2026 Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Interested persons may file written comments on this notice in accordance with 21 CFR 1303.11(c) (opens in a new tab) and 1315.11(d) (opens in a new tab). Electronic comments must be submitted, and written comments must be postmarked, on or before December 10, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised.
-
CMS Agency Information Collection Activities: Proposed Collection; Comment Request
Read More November 05, 2026The following comment period, while not directly effecting Prescription Drug Monitoring Programs (PDMPs), may have an indirect impact with the reporing by other entities and may be worth monitoring by PDMPs and stakeholders.
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
For additional information, see the following link: Federal Register :: Agency Information Collection Activities: Proposed Collection; Comment Request (opens in a new tab)
-
Recent Scheduling of Controlled Substances
Read More October 30, 2026There are three recent announcements from the Drug Enforcement Administration regarding the scheduling of controlled substances:
SCHEDULES OF CONTROLLED SUBSTANCES: PLACEMENT OF CENTANAFADINE IN SCHEDULE III
October 30, 2026. On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemically known as (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in schedule III of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing centanafadine, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible in schedule III of the CSA.The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/30/2026-22208/schedules-of-controlled-substances-placement-of-centanafadine-in-schedule-iii (opens in a new tab).
October 14, 2026. The Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine and mitragynine pseudoindoxyl (including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible) when either substance alone, or their combined amount if both are present, is above a specified threshold, in schedule I of the Controlled Substances Act (CSA). Based on a different threshold provided by the Department of Health and Human Services (HHS) in July of 2025, DEA published a notice of intent to temporarily schedule 7-hydroxymitragynine above that lower threshold on July 7, 2026. Additionally, DEA published a temporary order placing mitragynine pseudoindoxyl without a threshold in schedule I of the CSA on August 26, 2026. On October 8, 2026, HHS sent a letter recommending that DEA place of the CSA 7-hydroxymitragynine and mitragynine pseudoindoxyl in schedule I when either substance alone, or their combined amount if both are present, is above a new specified threshold. Based on the October 8, 2026 letter, DEA is issuing this notice of intent. While the new threshold recommended by HHS would permit certain products to remain in the marketplace without being subject to schedule I controls, neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels. When a temporary order is issued, it will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 7-hydroxymitragynine and/or mitragynine pseudoindoxyl above the specified threshold. In a separate document contained in this issue of the Federal Register , DEA is withdrawing the July 7, 2026 notice of intent related to 7-hydroxymitragynine. The August 26, 2026 temporary order placing mitragynine pseudoindoxyl in schedule I of the CSA without a threshold remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first. The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/14/2026-20943/schedules-of-controlled-substances-temporary-placement-of-7--hydroxymitragynine-and-mitragynine (opens in a new tab)
SCHEDULES OF CONTROLLED SUBSTANCES: TEMPORARY PLACEMENT OF MGM-15 AND MGM-16 IN SCHEDULE I
October 14, 2026. The Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule two 7-hydroxymitragynine-related substances (MGM-15 and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act (CSA). On August 26, 2026, DEA published a temporary order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I of the CSA. Today, DEA is providing notice of its intent to publish a new temporary order for MGM-15 and MGM-16 that will maintain the temporary placement of these substances in schedule I of the CSA without change. Separately in this Federal Register , DEA is publishing a notice of intent relating to mitragynine pseudoindoxyl, in response to a letter sent by the Department of Health and Human Services (HHS) dated October 6, 2026. HHS's letter related only to mitragynine pseudoindoxyl. Therefore, DEA is publishing this notice of intent only for the technical and procedural purpose of distinguishing MGM-15 and MGM-16 from mitragynine pseudoindoxyl. When issued, the temporary scheduling order addressing MGM-15 and MGM-16 will continue to impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these two 7-hydroxymitragynine-related substances. The August 26, 2026 temporary order placing these substances in schedule I of the CSA remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first. The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/14/2026-20942/schedules-of-controlled-substances-temporary-placement-of-mgm-15-and-mgm-16-in-schedule-i (opens in a new tab)
Our focus is to improve consistency among PDMPs, facilitate coordination between PDMPs and state and national stakeholders, increase PDMP efficiencies, measure performance and effectiveness, and promote best practices.
REQUEST PDMP TTA
Combat prescription misuse with RxCheck! Facilitate seamless data sharing among states, integrate with EHR systems, and join the nationwide PDMP movement. Developed with BJA support, RxCheck ensures secure data governance, empowering states to own and control their information.
LEARN MORE
